|
Dr Martens PLC on Tuesday reported mixed third-quarter trading with growth in the Americas offset by weak performances in Europe, Middle East & Africa, and Asia Pacific. The Northamptonshire, England-based boot maker said revenue fell 3.1% to £251 million for the 13 weeks ended December 28, or by 2.7% at constant currency, from a year earlier. Year-to-date revenue stands at £573 million, down 1.8% reported and 0.7% at constant currency. Dr Martens’ financial year runs to the end of March. ‘The revenue performance reflects the challenging consumer environment and our continued focus on improving the quality of our revenues by reducing clearance activity and taking a disciplined approach to promotions in direct to consumer thereby increasing the full price mix,’ the FTSE 250 listing explained. Shares in Dr Martens fell 8.1% to 69.55 pence each in London on Tuesday. Wholesale revenue rose 9.5% at constant currency, while direct-to-consumer declined 6.5%. By region, EMEA revenue dropped 6.0% at constant currency, while Americas grew 2.2%, and Asia Pacific fell 2.7%. Dr Martens said it continues to focus on ‘improving the quality of revenue’, with full-price direct-to-consumer sales up 2% year-to-date. Wholesale growth is ‘broad-based across all three regions’, while ecommerce remains flat as clearance activity is scaled back ‘and returned to a normal promotional calendar, as previously guided’. Dr Martens expects full-year revenue to be broadly flat at constant currency and said it is ‘comfortable’ with market expectations for financial 2026 pretax profit, which it expects to show ‘significant’ year-on-year growth. In the financial year to March 2025, Dr Martens posted revenue of £787.6 million, reported pretax profit of £8.8 million and adjusted pretax profit of £34.1 million. Chief Executive Officer Ije Nwokorie said: ‘This is a year of pivot, as we make the necessary changes to our business to set us up for future sustainable growth.’ Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
